• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Considerations in Pfizer-BioNTech COVID-19 vaccine preparation in clinic: Quality vs quantity.在临床中考虑辉瑞-生物科技公司 COVID-19 疫苗准备工作:质量与数量。
Am J Health Syst Pharm. 2022 Feb 18;79(5):325-327. doi: 10.1093/ajhp/zxab388.
2
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.辉瑞/生物科技和牛津/阿斯利康疫苗对沙特阿拉伯全国疫苗接种运动中真实环境下 COVID-19 发病率和死亡率的影响。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
3
A case of hemichorea following administration of the Pfizer-BioNTech COVID-19 vaccine.一例接种辉瑞-生物科技公司新冠疫苗后出现偏侧舞蹈症的病例。
Neurol Sci. 2022 Feb;43(2):771-773. doi: 10.1007/s10072-021-05763-5. Epub 2021 Nov 23.
4
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗:辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
5
Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.美国五家退伍军人事务医疗中心 2021 年 2 月 1 日至 9 月 30 日期间住院退伍军人中 Moderna 和辉瑞-BioNTech COVID-19 疫苗的有效性和抗体反应比较。
MMWR Morb Mortal Wkly Rep. 2021 Dec 10;70(49):1700-1705. doi: 10.15585/mmwr.mm7049a2.
6
Impaired memory B-cell response to the Pfizer-BioNTech COVID-19 vaccine in patients with common variable immunodeficiency.常见可变免疫缺陷患者对辉瑞-生物科技公司新冠疫苗的记忆B细胞反应受损。
J Allergy Clin Immunol. 2022 Jan;149(1):76-77. doi: 10.1016/j.jaci.2021.08.031. Epub 2021 Oct 19.
7
Three cases of vesiculobullous non-IgE-mediated cutaneous reactions to tozinameran (Pfizer-BioNTech COVID-19 vaccine).三例对托珠单抗(辉瑞-生物科技新冠疫苗)的非IgE介导的水疱大疱性皮肤反应
J Eur Acad Dermatol Venereol. 2021 Dec;35(12):e855-e857. doi: 10.1111/jdv.17581. Epub 2021 Aug 16.
8
First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine.接种辉瑞-生物科技公司新冠疫苗后多发性硬化症的首发表现。
J Neurol. 2022 Jan;269(1):55-58. doi: 10.1007/s00415-021-10648-w. Epub 2021 Jun 11.
9
Comments on "Initial clinical manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine" by , J Neuroimmunol.对[作者姓名]发表于《神经免疫学杂志》的《辉瑞 - 生物科技公司新冠疫苗接种后多发性硬化症的初始临床表现》的评论
J Neuroimmunol. 2022 Jan 15;362:577780. doi: 10.1016/j.jneuroim.2021.577780. Epub 2021 Nov 18.
10
Viral-like Reaction or Hypersensitivity? Erythema Multiforme Minor Reaction and Moderate Eosinophilia After the Pfizer-BioNTech BNT162b2 (mRNA-Based) SARS-CoV-2 Vaccine.病毒样反应还是超敏反应?辉瑞-生物科技公司BNT162b2(基于信使核糖核酸的)严重急性呼吸综合征冠状病毒2疫苗接种后的轻症多形红斑反应和中度嗜酸性粒细胞增多症
J Investig Allergol Clin Immunol. 2021 Feb 21;32(1):77-78. doi: 10.18176/jiaci.0757. Epub 2021 Sep 30.

在临床中考虑辉瑞-生物科技公司 COVID-19 疫苗准备工作:质量与数量。

Considerations in Pfizer-BioNTech COVID-19 vaccine preparation in clinic: Quality vs quantity.

机构信息

Therapeutic Development Branch National Center for Advancing Translational Sciences National Institutes of Health Rockville, MD, USA.

Center for Drug Evaluation and Research Food and Drug Administration Silver Spring, MD, USA.

出版信息

Am J Health Syst Pharm. 2022 Feb 18;79(5):325-327. doi: 10.1093/ajhp/zxab388.

DOI:10.1093/ajhp/zxab388
PMID:34634098
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8524502/
Abstract

In an effort to expedite the publication of articles , AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

摘要

为了加快文章的发表速度,AJHP 在接受后尽快将手稿在线发布。已接受的手稿已经经过同行评审和编辑,但在进行技术格式和作者校对之前在线发布。这些手稿不是记录的最终版本,稍后将用最终文章(按照 AJHP 风格格式化并由作者校对)替换。